Micronized device for the delivery of biologically active molecules and methods of use thereof
The invention provides micronized encapsulated cell therapy devices that are capable of delivering a biologically active molecule to the eye. Also provided are methods of using the same to deliver biologically active molecules to the eye and to treat ophthalmic disorders in patients suffering there from.
1. A micronized device for delivery of a therapeutic dose of a biologically active molecule to the eye comprising a capsule, the capsule comprising:
a) a core comprising between about 5×10 2 and 90×10 3 living cells that produce a biologically active molecule, wherein the core has a volume of less than 0.5 μl, and
b) a biocompatible jacket surrounding said core, the jacket having a molecular weight cutoff permitting diffusion of the biologically active molecule into the eye,
wherein the device is configured as a cylinder with an outer diameter of between 200 and 350 μm and a length of between 0.5 and 6 mm, wherein the therapeutic dosage of the biologically active molecule that diffuses into the eye is between 0.1 pg and 1000 ng per eye per patient per day for a period greater than three months.
2. The device of claim 1 , wherein the device further comprises a tether adapted for securing the capsule to an ocular structure.
3. The device of claim 2 , wherein the tether is selected from the group consisting of a loop, a disk, and a suture.
4. The device of claim 3 , wherein the tether comprises a shape memory material.
5. The device of claim 1 , wherein the biocompatible jacket comprises a permselective, immunoisolatory membrane.
6. The device of claim 1 , wherein the biocompatible jacket comprises an ultrafiltration or microporous membrane.
7. The device of claim 1 , wherein the biocompatible jacket comprises a polymer material.
8. The device of claim 7 , wherein the polymer material is selected from the group consisting of polyacrylonitrile-polyvinylchloride, polyacrylonitrile, polymethylmethacrylate, polyvinyldifluoride, polyolefins, polysulfones, polymide, and celluloses.
9. The device of claim 1 , wherein the device is implanted in the vitreous, the Subtenon's capsule, the periocular space, or the anterior chamber.
10. The device of claim 1 , wherein the biologically active molecule is selected from the group consisting of antiangiogenic factors, anti-inflammatory factors, neurotrophic factors, growth factors, trophic factors, antibodies and antibody fragments, neurotransmitters, hormones, cytokines, and lymphokines.
11. The device of claim 10 , wherein the biologically active molecule is a cytokine or a lymphokine.
12. The device of claim 10 , wherein the biologically active molecule is selected from the group consisting of TGFβ, GDNF, NGF, CNTF, bFGF, aFGF, IL-1β, IFN-β, IFN-α, BDNF, LIF, NT-4, NTN, NT4/5, CT-1, LEDGF, Neublastin, Axokine, IL-23, RdCVF, IL-10, Alpha INF, IL-1Rα, and Remicade.
13. The device of claim 10 , wherein the biologically active molecule is an antiangiogenic factor selected from the group consisting of vasculostatin, angiostatin, endostatin, anti-integrins, vascular endothelial growth factor inhibitors (VEGF-inhibitors), platelet factor 4, heparinase, bFGF-binding molecules, the VEGF receptor Flt, the VEGF receptor Flk, Lucentis, VEGF Trap, Tek Δ/Fc (ang1/ang2 inhibitor), 2×Con4 (C), soluble VEGF Receptors, and PEDF.
14. The device of claim 1 , wherein at least one additional biologically active molecule is delivered from the capsule to the eye.
15. The device of claim 14 , wherein the at least one additional biologically active molecule is from a cellular source.
16. The device of claim 14 , wherein the at least one additional biologically active molecule is from a noncellular source.
17. The device of claim 16 , wherein said at least one additional biologically active molecule is encapsulated in, dispersed within, or attached to one or more components of the micronized device.
18. The device of claim 16 , wherein said at least one additional biologically active molecule is selected from the group consisting of: nucleic acids, nucleic acid fragments, peptides, polypeptides, peptidomimetics, carbohydrates, lipids, organic molecules, inorganic molecules, therapeutic agents, and combinations thereof.
19. The device of claim 18 , wherein the therapeutic agents are selected from the group consisting of: anti-angiogenic drugs, steroidal and non-steroidal anti-inflammatory drugs, anti-mitotic drugs, anti-tumor drugs, anti-parasitic drugs, IOP reducers, peptide drugs, and other biologically active molecule drugs approved for ophthalmologic use.
20. The device of claim 1 , wherein the cells are selected from the group consisting of insulin-producing cells, adrenal chromaffin cells, antibody-secreting cells, fibroblasts, astrocytes, Beta cell lines, Chinese hamster ovary cells, and ARPE-19 cells.
21. The device of claim 20 , wherein the cells are allogeneic cells.
22. The device of claim 1 , wherein the cells are syngeneic cells.
23. The device of claim 1 , wherein the molecular weight cut off of the biocompatible jacket is between about 1 kD and about 150 kD.
24. The device of claim 1 , wherein the core further comprises a substantially non-degradable filamentous cell-supporting matrix, wherein the matrix comprises a plurality of monofilaments, and wherein said monofilaments are
(a) twisted into a yarn or woven into a mesh or
(b) twisted into a yarn that is in non-woven strands,
and wherein the cells or tissue are distributed thereon.
25. The device of claim 24 , wherein the filamentous cell-supporting matrix comprises a biocompatible material selected from the group consisting of acrylic, polyester, polyethylene, polypropylene polyacetonitrile, polyethylene terephthalate, nylon, polyamides, polyurethanes, polybutester, silk, cotton, chitin, carbon, and biocompatible metals.